Shape Therapeutics (ShapeTX) is a biotechnology company founded in 2018, specializing in the development of programmable RNA medicines to address various genetic disorders and complex diseases. By integrating artificial intelligence (AI) with RNA technology, ShapeTX aims to create treatments that are safe, effective, and accessible.

The company’s proprietary platform includes several key technologies:

• RNAfix®: This technology utilizes ADAR, a naturally occurring enzyme in human cells, to edit RNA sequences without making permanent changes to DNA. This approach can correct genetic mutations or intentionally introduce changes to treat a wide range of genetic disorders.
• AI-Driven Design: ShapeTX employs AI to design novel RNA molecules capable of reprogramming cells. This includes correcting mutations, fine-tuning gene expression, and modulating protein interactions, thereby expanding treatment possibilities for challenging diseases.
• Precise Delivery Systems: The company engineers viral capsids through its AI-driven platform to deliver RNA medicines accurately to specific tissues or cells, minimizing potential side effects and enhancing treatment efficacy.
• TruStable™ Manufacturing: ShapeTX has developed stable cell lines that improve the scalability of RNA medicine production, ensuring treatments can be manufactured efficiently to meet varying patient needs.

ShapeTX has secured significant funding to advance its research and development efforts. In a Series B funding round completed on July 15, 2021, the company raised $112 million, bringing its total funding to $147.5 million.

The company is headquartered in Seattle, Washington, with an additional location in Boston, Massachusetts.

ShapeTX’s leadership team comprises experts in biotechnology and business, including co-founder and Chief Financial Officer John Suliman, co-founder and Professor of Bioengineering at the University of California San Diego Prashant Mali, PhD, and Interim CEO and Chief Scientific Officer David Huss, PhD.

By leveraging the convergence of AI and RNA technologies, ShapeTX is at the forefront of developing innovative therapies aimed at treating a broad spectrum of diseases, including rare genetic disorders and neurodegenerative conditions such as Alzheimer’s and Parkinson’s.